MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.
Also called NCT06128629
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT06128629
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Portugal, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06128629. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-13 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Condition
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Biological)
- NTLA-2001
- Intervention (Drug)
- Placebo
- Lead sponsor
- Intellia Therapeutics
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct06128629- Content hash
9f5a46335ac2e6b7fdead7284146b3de516864d24116d0c19cedc0a56649ff96